Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company’s Facility in Israel
false
÷îäãò áò"î
2
380
KAMADA LTD
Corporation no:
511524605
14096
Israel Securities Authority
Tel Aviv Stock Exchange
C002
(
Public
)
Reported via MAGNA:
03/05/2023
www.isa.gov.il
www.tase.co.il
Reference:
2023-02-040750
Time of broadcast:
13:56
13:56
Immediate Report
Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company’s Facility in Israel
proval_-_V002_clean_-_ACC-PDFUA_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market:
TASE
Date of revision of form structure:
02/05/2023
Address:
Holtzman 2
4081
,
Rehovot
7670402
ISRAEL
,
Tel:
08-9406472
,
Fax:
08-9406473
E-mail address:
liorf@kamada.com
Company site:
www.kamada.com
Previous names of reporting entity:
Name of the Signatory:
REFAEL MOSHE
Position of Signatory in the reporting corporation:
Company Controller
Name of Employer Company:
Address:
Holtzman
2
,
Rehovot
7670402
Telephone:
08-9406472
Facsimile:
08-9406473
E-mail:
mosheb@kamada.com
1